Ceregene Lands $11,500,000 Series D Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d3ee755b-9133-4ccd-a241-92b9765588a6&Preview=1 -
Date
11/11/2010 -
Company Name
Ceregene -
Mailing Address
9381 Judicial Drive San Diego, CA 92121 -
Company Description
Using gene therapy delivery systems, Ceregene’s primary focus is the discovery and development of novel genetic therapeutics for the treatment of neurological disorders. Ceregene aims to be the leader in the field of Central Nervous System (CNS) disease treatment using molecular medicine, an area of great unmet medical need. -
Website
http://www.ceregene.com -
Transaction Type
Venture Equity -
Transaction Amount
$11,500,000 -
Transaction Round
Series D -
Proceeds Purposes
The funds will be used to help support Ceregene’s currently enrolling Phase 2b clinical study of CERE-120 for the treatment of Parkinson’s disease. -
M&A Terms
-
Venture Investor
Hamilton BioVentures -
Venture Investor
Alta Partners -
Venture Investor
MPM Capital -
Venture Investor
Investor Growth Capital
